Taro's granisetron tablets receive FDA approval

NewsGuard 100/100 Score

Taro Pharmaceutical Industries Ltd. ("Taro," the "Company," Pink Sheets: TAROF) reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").

Taro's granisetron tablets is a prescription product used for the prevention of nausea and vomiting associated with chemotherapy and radiation treatment and is bioequivalent to Hoffman-La Roche, Inc.'s Kytril® tablets, 1 mg (base). According to industry sources, granisetron tablets had U.S. sales of approximately $15 million in 2009.

Source:

Taro Pharmaceutical Industries Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
World's first human mini-brain with a fully functional blood-brain barrier developed